Metastatic Castration-resistant Prostate Cancer Market Poised for Strong Growth by 2036, Due to the Launch of Drug Classes Such as Anti-B7-H3 ADC, PROTAC Protein Degrader, NTD AR Inhibitor, Radionuclide Therapy, and Several Others | DelveInsight

Summary

Market analysis report from DelveInsight projects strong growth in the metastatic castration-resistant prostate cancer market through 2036, driven by multiple novel drug classes in late-stage development including Anti-B7-H3 ADCs, PROTAC protein degraders, NTD AR inhibitors, and radionuclide therapies.